Skip to main content

Advertisement

SpringerLink
Log in

Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities

  • Lower Gastrointestinal Cancers (AB Benson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms characterized by varied biological hallmarks and behavior, ranging from indolent to aggressive. For many decades, somatostatin analogues and few targeted therapies were available for NETs and these therapies had minimal response rates. However, there have been a number of recent treatment advances. Peptide receptor radionuclide therapy (PRRT) is a novel approach to treatment of NETs and has changed the landscape of treatment for NETs. It is a form of targeted therapy in which a radiolabeled somatostatin analogue delivers radiation specifically to tumor cells expressing the somatostatin receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kloppel G, Dege K, Remmele W, Kapran Y, Tuzlali S, Modlin IM. Siegfried Oberndorfer: a tribute to his work and life between Munich, Kiel, Geneva, and Istanbul. Virchows Arch. 2007;451(Suppl 1):S3–7.

    Article  PubMed  Google Scholar 

  2. • Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42 Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the USA; SEER data from 1973 to 2012.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.

    Article  CAS  PubMed  Google Scholar 

  4. Mittra ES. Neuroendocrine tumor therapy: (177)Lu-DOTATATE. AJR Am J Roentgenol. 2018;211(2):278–85.

    Article  PubMed  Google Scholar 

  5. •• Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35 First phase 3 multicenteric, randomized controlled, parallel-group study of 177Lu-DOTATATE plus long-acting octreotide as compared with high-dose octreotide in patients with advanced midgut neuroendocrine tumors (NETTER-1) which led to the approval of PRRT with 177Lu-DOTATATE in advanced NETs in the USA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017;58(Suppl 2):3S–9S.

    Article  CAS  PubMed  Google Scholar 

  7. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724–9.

    Article  CAS  PubMed  Google Scholar 

  9. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  10. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41(10):1704–13.

    CAS  PubMed  Google Scholar 

  11. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–22.

    Article  PubMed  Google Scholar 

  12. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):61S–6S.

    Article  CAS  PubMed  Google Scholar 

  13. Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Limouris GS, Poulantzas V, Trompoukis N, Karfis I, Chondrogiannis S, Triantafyllou N, et al. Comparison of 111In-[DTPA0]octreotide versus non carrier added 177Lu- [DOTA0,Tyr3]-octreotate efficacy in patients with GEP-NET treated intra-arterially for liver metastases. Clin Nucl Med. 2016;41(3):194–200.

    Article  CAS  PubMed  Google Scholar 

  15. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38(5):358–66.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hindie E, Morgat C, Zanotti-Fregonara P, Haissaguerre M, Bordenave L, Tabarin A. Advantages and limits of targeted radionuclide therapy with somatostatin antagonists. J Nucl Med. 2018;59(3):546–7.

    Article  CAS  PubMed  Google Scholar 

  17. Navalkissoor S, Grossman A. Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy. Neuroendocrinology. 2019;108(3):256–64.

    Article  CAS  PubMed  Google Scholar 

  18. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23–9.

    Article  PubMed  Google Scholar 

  19. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010;10 Spec(A):S83–91.

    Article  Google Scholar 

  20. Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm. 2009;24(5):527–33.

    Article  CAS  PubMed  Google Scholar 

  21. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–56.

    Article  PubMed  Google Scholar 

  22. Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging. 2010;37(10):1869–75.

    Article  CAS  PubMed  Google Scholar 

  23. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24.

    Article  CAS  PubMed  Google Scholar 

  24. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.

    Article  CAS  PubMed  Google Scholar 

  25. Strosberg JR, Wolin EM, Chasen BA, Kulke MH, Bushnell DL, Caplin ME, et al. First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. Journal of Clinical Oncology. 2018;36(15_suppl):4099.

    Article  Google Scholar 

  26. Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42(8):1238–46.

    Article  CAS  PubMed  Google Scholar 

  27. Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845–51.

    Article  CAS  PubMed  Google Scholar 

  28. Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347–54.

    Article  CAS  PubMed  Google Scholar 

  29. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.

    Article  CAS  PubMed  Google Scholar 

  30. • Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60(7):937–43 2019 Joint North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging consensus guideline for the administration of PRRT.

    Article  CAS  PubMed  Google Scholar 

  31. • Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309 2017 European Neuroendocrine Tumor Society Consensus Guidelines for inclusion of peptide receptor radionuclide therapy.

    Article  CAS  PubMed  Google Scholar 

  32. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy with (177)Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. AJR Am J Roentgenol. 2019;213(2):309–17.

    Article  PubMed  Google Scholar 

  34. Yu NY, Rule WG, Sio TT, Ashman JB, Nelson KL. Radiation contamination following cremation of a deceased patient treated with a radiopharmaceutical. JAMA. 2019;321(8):803–4.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kwekkeboom DJ, WWd H, Kam BL, Eijck CH, Mv E, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.

    Article  CAS  PubMed  Google Scholar 

  36. Kesavan M, Claringbold PG, Turner JH. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology. 2014;99(2):108–17.

    Article  CAS  PubMed  Google Scholar 

  37. Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17–23.

    Article  CAS  PubMed  Google Scholar 

  38. Lee ST, Kulkarni HR, Singh A, Baum RP. Theranostics of neuroendocrine tumors. Visc Med. 2017;33(5):358–66.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28(10):1552–4.

    Article  CAS  PubMed  Google Scholar 

  40. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23.

    Article  CAS  PubMed  Google Scholar 

  41. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9–15.

    Article  CAS  PubMed  Google Scholar 

  42. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83S–91S.

    CAS  PubMed  Google Scholar 

  43. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 1995;31(5):1249–56.

    Article  CAS  PubMed  Google Scholar 

  44. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175–84.

    Article  CAS  PubMed  Google Scholar 

  45. Riff BP, Yang YX, Soulen MC, Pryma DA, Bennett B, Wild D, et al. Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin Nucl Med. 2015;40(11):845–50.

    Article  PubMed  Google Scholar 

  46. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BLR, van Essen M, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35(4):749–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Davi MV, Bodei L, Francia G, Bartolomei M, Oliani C, Scilanga L, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Investig. 2006;29(6):563–7.

    Article  CAS  Google Scholar 

  48. Tapia Rico G, Li M, Pavlakis N, Cehic G, Price TJ. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev. 2018;66:1–6.

    Article  PubMed  Google Scholar 

  49. Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6(1):7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.

    Article  PubMed  CAS  Google Scholar 

  51. Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Ann Nucl Med. 2018;32(3):217–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lawal I, Louw L, Warwick J, Nyakale N, Steyn R, Lengana T, et al. The College of Nuclear Physicians of South Africa Practice Guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours. S Afr J Surg. 2018;56(3):55–64.

    CAS  PubMed  Google Scholar 

  53. Wright MF, Cates J, Gonzalez RS, Das S, Berlin JD, Shi C. Impact of peritoneal metastasis on survival of patients with small intestinal neuroendocrine tumor. Am J Surg Pathol. 2019;43(4):559–63.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Merola E, Prasad V, Pascher A, Pape UF, Arsenic R, Denecke T, et al. Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options. Neuroendocrinology. 2019.

  55. de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42(1):47–56.

    Article  PubMed  CAS  Google Scholar 

  56. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.

    Article  CAS  PubMed  Google Scholar 

  57. Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24(19):4672–9.

    Article  CAS  PubMed  Google Scholar 

  58. Pignata2019, Pignata SA, Ferrantelli A, Baldari S. Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment. Clinical and Translational Imaging. 2019;7(5):373–6.

    Article  Google Scholar 

  59. Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46(3):696–703.

    Article  CAS  PubMed  Google Scholar 

  60. LUTATHERA® [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; July 2018.

  61. Hromadik LK, Sturges L. Caring for patients receiving 177Lu-DOTATATE, Lutathera®: a treatment of hope for patients with gastroenteropancreatic neuroendocrine tumors. J Radiol Nurs. 2019;38(1):28–32.

    Article  Google Scholar 

  62. Forrer FUH, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(08):1310–6.

    CAS  PubMed  Google Scholar 

  63. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51(3):383–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Oncology, Stanford University, School of Medicine, Stanford, CA, 94305, USA

    Shagufta Shaheen MD & Pamela L. Kunz MD

  2. Department of Radiology, Division of Nuclear Medicine, Stanford University, School of Medicine, Stanford, CA, 94305, USA

    Farshad Moradi MD, PhD

  3. Brigham Young University, 22234 S Vermont Ave. #203, Torrance, CA, 90502, USA

    Gerardo Gamino BS

Authors
  1. Shagufta Shaheen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farshad Moradi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerardo Gamino BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamela L. Kunz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pamela L. Kunz MD.

Ethics declarations

Conflict of Interest

Shagufta Shaheen declares that she has no conflict of interest.

Farshad Moradi declares that he has no conflict of interest.

Gerardo Gamino declares that he has no conflict of interest.

Pamela L. Kunz has received funding for clinical trials paid to her institution by Advanced Accelerator Applications, Ipsen, Lexicon Pharmaceuticals, Xencor, and Brahms GmbH (Thermo Fisher Scientific); and has received compensation for service on advisory boards from Advanced Accelerator Applications, Ipsen, Lexicon Pharmaceuticals, and Novartis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lower Gastrointestinal Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaheen, S., Moradi, F., Gamino, G. et al. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Curr. Treat. Options in Oncol. 21, 25 (2020). https://doi.org/10.1007/s11864-020-0711-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-0711-9

Keywords

Search

Navigation